PTGX Stock Price
PTGX
PTGX stock price is $135.26 (-5.66% on the day), giving PTGX a market cap of $9.28B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
PTGX Stock Overview
- Price
- $135.26
- Previous close
- $143.37
- Open
- $142.56
- Market cap
- $9.28B
- 1-year price target
- $176.88
- MarketXLS Rank
- 53
About PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PTGX | $135.26 | -5.7% | 582.61K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |